Skip to main content
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. — Investor Relations & Filings

Ticker · OKUR ISIN · US75974E1038 US Manufacturing
Open in API
Filings indexed 340 across all filing types
Latest filing 2025-04-02 Director's Dealing
Country US United States of America
Listing US OKUR

About OnKure Therapeutics, Inc.

https://onkuretherapeutics.com/

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for cancer patients. The company is building a pipeline of potentially best-in-class, tumor-agnostic therapies that target biologically validated drivers of cancers, particularly those underserved by current treatments. Its research and development efforts are centered on novel and potentially less toxic kinase inhibitor drugs and epigenetic therapies.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2025-04-02 English
Director's Dealing 2025
Director's Dealing
2025-04-02 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to the resale of shares of Class A Common Stock issued in a private placement (PIPE Financing). It includes detailed information about the securities offered, risk factors, management discussion and analysis, business overview, and other disclosures typical of a prospectus used in securities registration and resale. The document is not a financial report, earnings release, management discussion, or any other report type but rather a registration and offering document for securities. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is lengthy (15,000 characters) and contains detailed information about the offering and related disclosures, confirming it is not merely an announcement but the actual prospectus filing.
2025-03-24 English
Regulatory Filings 2025
Regulatory Filings
2025-03-24 English
POS AM
Regulatory Filings Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to a Form S-1 Registration Statement filed with the SEC by OnKure Therapeutics, Inc. It references the inclusion of the fiscal year ended December 31, 2024 financial statements contained in the Annual Report on Form 10-K for the year ended December 31, 2024, which was filed on March 10, 2025. The document primarily serves to amend the registration statement and update disclosures based on the 10-K filing. It is a regulatory filing related to securities registration and amendments, not the actual annual report or financial statements themselves. The document is lengthy (15,000 characters) and contains detailed legal and regulatory information about the registration and merger transactions, but it is not a standalone financial report or earnings release. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2025-03-20 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by OnKure Therapeutics, Inc. It registers additional shares of common stock reserved for issuance under equity incentive and employee stock purchase plans. The document includes legal and procedural information typical of registration statements for securities offerings under employee benefit plans. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to share issuance and equity plans. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is the actual filing, not just an announcement or reference to another report.
2025-03-10 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.